

MEDICINES CO /DE  
Form 8-K  
January 20, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **January 16, 2006**

**The Medicines Company**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-31191**  
(Commission  
File Number)

**04-3324394**  
(IRS Employer  
Identification No.)

**8 Campus Drive**  
**Parsippany, New Jersey**  
(Address of Principal Executive Offices)

**07054**  
(Zip Code)

Registrant's telephone number, including area code: **(973) 656-1616**

(Former Name or Former Address, if Changed Since Last Report)

## Edgar Filing: MEDICINES CO /DE - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01. Entry into a Material Definitive Agreement**

On January 16, 2006, the Compensation Committee of the Board of Directors of The Medicines Company (the Company) approved 2005 annual cash bonus payments for the Company's executive officers in 2005. The Compensation Committee approved the bonus awards following an assessment of the Company's achievement of its goals for 2005 and the individual performance of each executive officer during 2005, in accordance with the Company's annual incentive plan. The following annual bonus payments were approved:

	<b>2005 Annual Bonus Payment</b>	
Clive A. Meanwell Chief Executive Officer	\$	200,000
John P. Kelley President and Chief Operating Officer	\$	120,000
Steven H. Koehler Senior Vice President and Chief Financial Officer	\$	100,000
John D. Richards Vice President	\$	60,996
Paul M. Antinori Vice President and General Counsel	\$	80,000

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE MEDICINES COMPANY

Date: January 20, 2006

By: /s/ Steven H. Koehler  
Steven H. Koehler  
Senior Vice President and Chief Financial Officer